Cover Image
市場調查報告書

全球核醫學市場:成長,趨勢,預測

Global Nuclear Medicine Market - Growth, Trends & Forecasts (2016 - 2021)

出版商 Mordor Intelligence LLP 商品編碼 319327
出版日期 內容資訊 英文 211 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
全球核醫學市場:成長,趨勢,預測 Global Nuclear Medicine Market - Growth, Trends & Forecasts (2016 - 2021)
出版日期: 2016年08月01日 內容資訊: 英文 211 Pages
簡介

核醫學市場預測到2015年將達到16億9,000萬美元。癌症和心臟病的發病率上升,對放射性醫藥品的意識提升,放射性醫藥品的取得成為帶動市場的主要因素。再加上SPECT和PET的認識度提升也加速了市場的成長。

本報告提供全球核醫學市場相關調查,提供您市場概要和規模,促進成長要素,阻礙要素,以及各診斷,治療,用途,地區趨勢,並彙整主要的參與企業競爭環境與簡介等資料。

第1章 簡介

第2章 摘要整理

第3章 市場概要

  • 放射性醫藥品定義
  • 市場規模
  • 市場佔有率
  • 市場趨勢
  • 推動市場的要素
    • 癌症和心臟病的發病率上升
    • 放射性醫藥品的SPECT和PET分析使用擴大
    • 放射性醫藥品的認知度提高
    • 大眾的意識
    • 放射性醫藥品的取得
  • 阻礙市場的要素
    • 放射性醫藥品的半衰期短
    • 高額的資本投資
    • 法律規章指南
    • 給付問題
  • 機會
    • 開發平台的潛在放射性元素
    • 神經學應用的擴大
    • 迴旋加速器生產
  • 威脅
    • 核子反應爐的封閉

第4章 診斷別市場區隔

  • 診斷市場
  • SPECT放射性元素
  • PET放射性元素
  • 氟18

第5章 各個治療市場區隔

  • β輻射體
  • α發射體
  • 近距離放射治療

第6章 各用途市場區隔

  • SPECT
  • PET
  • 治療的應用

第7章 各地區市場區隔

  • 簡介
  • 診斷市場
  • 北美
  • 亞太地區

第8章 競爭環境

  • 收購·合併
  • 新產品上市
  • 協定與聯合
  • 擴大

第9章 市場上龍頭企業

  • Covidien
  • IBA Group
  • Lantheus Medical Imaging
  • Triad Isotopes
  • Siemens Healthcare (PETNET Solutions)
  • NTP Radioisotopes

第10章 企業簡介

  • Bracco Imaging S.P.A.
  • Cambridge Isotope Laboratories, Inc.
  • Cardinal Health, Inc.
  • Covidien, Plc
  • Eczacibasi-Monrol
  • Fujifilm Holdings Corporation
  • Ge Healthcare
  • Iba Group
  • Isotec, Inc. (Sigma-Aldrich)
  • Lantheus Medical Imaging, Inc.
  • Nordion, Inc.
  • Ntp Radioisotopes (PTY), Ltd.
  • Petnet Solutions, Inc.
  • 太陽日酸株式會社
  • Urenco Limited
  • Rotem Industries, Ltd., Inc.
  • 相關機關

第11章 附錄

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄

The global nuclear medicines market is expected to reach USD 17,600 million by the end of 2020, growing at a CAGR of around 12.29% from 2015 to 2020. Nuclear medicine utilizes the radioisotope for application in diagnosis and treatment of diseases. The drugs containing radionuclides are called radiopharmaceuticals. The uses in radiological imaging include Magnetic Resonance Imaging (MRI), Computerized tomography (CT), Positron Emission Tomography (PET) and Single Proton Emission Tomography (SPECT).

The use of nuclear medicines for diagnostic purposes has gained huge popularity all around the world. There has been increased use of SPECT, PET, CT, and MRI for diagnosis of cardiac diseases, brain diseases, cancer and many others. Nuclear medicine is being used for therapeutic purposes for treatment of Alzheimer‰Uªs disease, coronary heart diseases, bone metastasis, cancers and different medical conditions affecting the thyroid gland, and scar tissue removal. Advancement in diagnostic imaging is bringing in more use of nuclear medicine. Nuclear cardiology has gained great popularity in North America.

Global Nuclear Medicines Market- Market Dynamics

The report lists several driving and restraining factors for the global nuclear medicines market. In addition, it sheds light on several opportunities that exist for the market players. Some of these are listed below.

Drivers

  • Increasing incidence and prevalence of cancer and cardiac ailments
  • Increasing application of SPECT and PET with advancement of technology
  • Growing awareness amongst physicians
  • Public awareness for better healthcare

Restraints

  • Short half-life of radiopharmaceuticals
  • High capital investment required for development
  • Stringent regulatory guidelines

Opportunities

  • Increasing imaging technologies
  • Potential radioisotopes in pipeline
  • Increasing neurological applications and cyclotron based production

The global nuclear medicine market has been segmented based on type, application, and geography.

Based on the type of product, the market has been segmented into the diagnostic market and therapeutic market, wherein the diagnostics market has been further subdivided into SPECT radioisotopes that include Technetium-993, Thallium-201, Iodine-123, Gallium and PET radioisotopes (subdivided intoRubidium-82, Flourine-18). The therapeutics category has been segmented into Alpha emitters (Radium-223), Beta Emitters (includes Iodine-131, Samarium-153, Lutetium-177, Yttrium-90) and Brachytherapy (includes iodine-125, Cesium-131, Palladium-103, & Iridium-192).

The segmentation based on the application has been similarly subdivided based on diagnostic and therapeutic application. The diagnostic application includes the application of SPECT and PET in cardiology, neurology, oncology and others. The therapeutic applications include application in oncology, thyroid, endocrinology and various other therapeutic areas.

The global nuclear medicine market has been geographically segmented into North America (includes United States, Canada, and Mexico), Europe (includes Germany, UK, France, Italy Spain, Russia and Others), Asia-Pacific (includes China, Japan, India, Australia South Korea and Others), Middle East and Africa (includes UAE, Saudi Arabia, Israel, and others), and Latin America (includes Brazil, Argentina, Mexico, and others). Due to high technological advancement coupled with a developed economy, North America has the largest market share, followed by Europe and Asia-Pacific.

Currently, the segment of diagnostics holds the largest share in nuclear medicines market, where SPECT has the largest share. In the segmentation based on type, the Beta Emitters hold the largest share.

Some of the key players in the market are:

  • Bracco Imaging S.P.A.
  • BRACCO PHARMA
  • Cambridge Isotope Laboratories, Inc.
  • Cardinal Health, Inc.
  • Fujifilm Holdings Corporation
  • GE Healthcare (Subsidiary of General Electric Company)
  • Nordion, Inc.
  • Taiyo Nippon Sanso Corporation

What the Report Offers

  • Market definition for the nuclear medicines market along with identification of key drivers and restraints for the market.
  • Market analysis for the nuclear medicines market, with region-specific assessments and competition analysis on a global and regional scale.
  • Identification of factors instrumental in changing the market scenario, rising prospective opportunities and identification of key companies that can influence the market on a global and regional scale.
  • Extensively researched competitive landscape section with profiles of major companies along with their strategic initiatives and market share.
  • Identification and analysis of the macro and micro factors that affect the nuclear medicines market on both global and regional scale.
  • A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information.

Table of Contents

1. INTRODUCTION

  • 1.1. REPORT DESCRIPTION
  • 1.2. MARKETS COVERED
  • 1.3. MAJOR STAKEHOLDERS
  • 1.4. RESEARCH METHODOLOGY

2. EXECUTIVE SUMMARY

3. MARKET OVERVIEW

  • 3.1. Market Drivers
    • 3.1.1. Increasing Incidents of Cancer and Cardiac Ailments
    • 3.1.2. Increasing SPECT AND PET applications
    • 3.1.3. Growing Public Awareness for healthcare
  • 3.2. MARKET CONSTRAINTS
    • 3.2.1. Short Half-life of Radiopharmaceuticals
    • 3.2.2. High Capital Investment
    • 3.2.3. Regulatory Guidelines
    • 3.2.4. Reimbursement
  • 3.3. OPPORTUNITIES
    • 3.3.1. Increasing Imaging Technologies
    • 3.3.2. Potential Radioisotopes in Pipeline
    • 3.3.3. Increasing Neurological Applications
    • 3.3.4. Cyclotron based production
  • 3.4. THREATS
    • 3.4.1. Shutdown of Nuclear Reactors

4. GLOBAL NUCLEAR MEDICINE MARKET SEGMENTATION

  • 4.1. Introduction
  • 4.2. Global Market: Segmentation by Diagnostics
    • 4.2.1. Introduction
    • 4.2.2. SPECT Market
    • 4.2.3. PET Market
  • 4.3. Global Market: Segmentation by Therapeutics
    • 4.3.1. Introduction
    • 4.3.2. Alpha Emitters
    • 4.3.3. Beta Emitters
    • 4.3.4. Brachytherapy
  • 4.4. GLOBAL MARKET SEGMENTATION BY APPLICATION
    • 4.4.1. SPECT Market
    • 4.4.2. PET Market
  • 4.5. MARKET SEGMENTATION BY GEOGRAPHY
    • 4.5.1. North America Nuclear Medicine Market
      • 4.5.1.1. UNITED STATES
      • 4.5.1.2. CANADA
      • 4.5.1.3. MEXICO
    • 4.5.2. EUROPE
      • 4.5.2.1. GERMANY
      • 4.5.2.2. UNITED KINGDOM
      • 4.5.2.3. FRANCE
      • 4.5.2.4. SPAIN
      • 4.5.2.5. ITALY
    • 4.5.3. ASIA - PACIFIC
      • 4.5.3.1. India
      • 4.5.3.2. China
      • 4.5.3.3. South Korea
      • 4.5.3.4. Japan

5. COMPETITIVE LANDSCAPE

  • 5.1. MERGERS, ACQUISITIONS & SPIN OFFS
  • 5.2. COLLABORATIONS
  • 5.3. PRODUCT LAUNCHES

6. PROFILES OF KEY COMPANIES

  • 6.1. MALLINCKRODT
  • 6.2. LANTHEUS MEDICAL IMGAGING
  • 6.3. IBA GROUP
  • 6.4. TRIAD ISOTOPE
  • 6.5. SIEMENS HEALTHCARE
  • 6.6. NTP RADIOISOTOPES
  • 6.7. Bracco Imaging S.P.A.
  • 6.8. BRACCO PHARMA
  • 6.9. Cambridge Isotope Laboratories, Inc.
  • 6.10. Cardinal Health, Inc.
  • 6.11. GE Healthcare (Subsidiary of General Electric Company)
  • 6.12. Nordion, Inc.
  • 6.13. Taiyo Nippon Sanso Corporation
  • 6.14. Fujifilm Holdings Corporation
  • 6.15. Eczacibasi-Monrol
  • 6.16. Isotec, Inc. (Sigma-Aldrich)
  • 6.17. Petnet Solutions, Inc. (A Subsidiary Of Siemens Medical Solutions Usa, Inc.)

7. Appendix

  • 7.1. Abbreviations
  • 7.2. Sources
  • 7.3. Bibliography
  • 7.4. Disclaimer
Back to Top